Resources Repository
-
ReviewPublication 2016Choosing an Epidemiological Model Structure for Economic Evaluation
This review presents a taxonomy of epidemiological model structures and applies it to the economic …
This review presents a taxonomy of epidemiological model structures and applies it to the economic evaluation of public health interventions for non-communicable diseases. Growing pressures on health services and on social care have led to a greater need for prevention of chronic diseases. In order for decision makers to make informed judgements about how to best spend finite public health resources, they must be able to quantify the anticipated costs, benefits, and opportunity costs of…
Environmental Health | Chronic Disease/Risk | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Dynamic Simulation | Social Determinants | Health Systems | Climate/Environment | Culture/Society | Health/Medicine -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Chronic Disease/Risk | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Child/Nutrition | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | North America -
GuidelinesPublication 2013Decision and Simulation Modeling in Systematic Reviews
The purpose of this review is to provide guidance for determining when incorporating a decision-analytic …
The purpose of this review is to provide guidance for determining when incorporating a decision-analytic model alongside a systemic review would be of added value for decision making purposes. The purpose of systematic reviews is to synthesize the current scientific literature on a particular topic in the form of evidence reports and technology assessments to assist public and private organizations in developing strategies that improve the quality of health care and decision making. However, there…
Chronic Disease/Risk | Infectious Diseases | Evidence Synthesis | Mathematical Models | Decision Analysis | Child/Nutrition | Health/Medicine | North America -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Chronic Disease/Risk | Infectious Diseases | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
GuidelinesPublication 2011HPV Vaccine Introduction in LMIC's: Guidance on the Use of Cost-Effectiveness Models
This article is a literature review of HPV vaccination models suitable for low-income and middle-income …
This article is a literature review of HPV vaccination models suitable for low-income and middle-income country use to provide information about the feasibility of using such models in a developing country setting. The authors evaluated models in terms of their capacity, requirements, limitations and comparability. Their literature review identified six HPV vaccination models suitable for low-income and middle-income country use and representative of the literature in terms of provenance and model structure. Each model was…
Chronic Disease/Risk | Infectious Diseases | Mathematical Models | Calibration/Validation | Cost-Effectiveness Analysis | Health Systems | Clinical Care | Health/Medicine | Science/Technology | Global -
ReviewPublication 2008Modeling Cervical Cancer Prevention in Developed Countries
Decision-analytic models are increasingly developed to simulate disease burden and interventions in different settings in …
Decision-analytic models are increasingly developed to simulate disease burden and interventions in different settings in order to evaluate the benefits and cost-effectiveness of primary and secondary interventions. This article is a review of mathematical models that have been used to evaluate HPV vaccination in the context of developed countries with existing screening programs. Despite variations in model assumptions and uncertainty in existing data, pre-adolescent vaccination of females in the setting of current screening practices has…
Chronic Disease/Risk | Infectious Diseases | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Calibration/Validation | Health/Medicine | Science/Technology -
ReviewPublication 2006Public Health Policy for Cervical Cancer Prevention: Decision Science, Economic Evaluation, & Mathematical Modeling
Several factors are changing the landscape of cervical cancer control, including a better understanding of …
Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of human papillomavirus (HPV), reliable assays for detecting high-risk HPV infections, and a soon to be available HPV-16/18 vaccine. There are important differences in the relevant policy questions for different settings. By synthesizing and integrating the best available data, the use of modeling in a decision analytic framework can identify those factors most likely to influence outcomes,…
Chronic Disease/Risk | Infectious Diseases | Mathematical Models | Decision Analysis | Cost-Effectiveness Analysis | Economics/Finance | Health/Medicine | Science/Technology | Global -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Chronic Disease/Risk | Infectious Diseases | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Health/Medicine | Global -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Chronic Disease/Risk | Cost-Effectiveness Analysis | Health/Medicine | North America